The partition-defective 3 (PAR-3) protein is implicated in the formation of tight junctions at epithelial cell-cell contacts. We investigated DNA copy number aberrations in human esophageal squamous cell carcinoma (ESCC) cell lines using a high-density oligonucleotide microarray and found a homozygous deletion of PARD3 (the gene encoding PAR-3). Exogenous expression of PARD3 in ESCC cells lacking this gene enhanced the recruitment of zonula occludens 1 (ZO-1), a marker of tight junctions, to sites of cell-cell contact. Conversely, knockdown of PARD3 in ESCC cells expressing this gene caused a disruption of ZO-1 localization at cell-cell borders. A copy number loss of PARD3 was observed in 15% of primary ESCC cells. Expression of PARD3 was significantly reduced in primary ESCC tumors compared with their nontumorous counterparts, and this reduced expression was associated with positive lymph node metastasis and poor differentiation. Our results suggest that deletion and reduced expression of PARD3 may be a novel mechanism that drives the progression of ESCC.
Introduction
Esophageal cancer is the sixth leading cause of cancer mortality worldwide (Enzinger and Mayer, 2003) . Of the two main histological subtypes of esophageal cancer, squamous cell carcinoma is prevalent worldwide, although the incidence of adenocarcinoma has been increasing in North America and Europe (Vizcaino et al., 2002) .
Inactivation of tumor suppressor genes is critical to the development and progression of human malignancies. Much effort has been put into finding homozygous deletions in cancer cells in the expectation that they harbor tumor suppressor genes. Suppressor genes that have been identified partly from homozygous deletions include CDKN2A (Kamb et al., 1994) , PTEN (Li et al., 1997) and SMAD4 (Hahn et al., 1996) . The recent introduction of high-density oligonucleotide microarrays designed for typing of single nucleotide polymorphisms (SNPs) facilitates high-resolution mapping of chromosomal amplifications, deletions and losses of heterozygosity (Mei et al., 2000; Zhao et al., 2004) .
Cell polarization and the formation of cell-cell junctions are coupled processes that are essential to tissue morphogenesis (Macara, 2004) . Loss of cell-cell adhesion and cell polarity is commonly observed in advanced tumors and correlates strongly with their invasion into adjacent tissues and the formation of metastases (Wodarz and Na¨thke, 2007) .
It has become apparent that polarity is largely regulated by a conserved set of proteins referred to as partition-defective (PAR) proteins (Kemphues et al., 1988; Macara, 2004; Suzuki and Ohno, 2006) . These proteins were first identified in the zygote of Caenorhabditis elegans, where they specify the anterior-posterior body axis. They are also essential for asymmetric cell division in Drosophila melanogaster. The mammalian homologs of the C. elegans polarity proteins have evolutionarily conserved functions in the establishment of cell polarity in various cell types. One of these homologs, PAR-3, contains one self-oligomerization domain in the N terminus, three PDZ protein interaction domains and one atypical protein kinase C (aPKC)-binding domain (Izumi et al., 1998; Joberty et al., 2000; Lin et al., 2000; Asse´mat et al., 2008) . These domains enable PAR-3 to form a conserved protein complex with PAR-6 and aPKC (Macara, 2004; Suzuki and Ohno, 2006) . In mammalian epithelial cells, this PAR-3-PAR-6-aPKC complex assembles at tight junctions, where it is necessary for the establishment of apico-basal polarity.
Thus, deletion of PAR protein genes in tumor cells may disrupt cell polarity and adhesion. To identify the genes that are potentially involved in human esophageal squamous cell carcinoma (ESCC), we investigated DNA copy number aberrations in ESCC cell lines using highresolution SNP arrays. We show that the gene encoding human PAR-3 protein, PARD3, is homozygously deleted in ESCC cells, and that this deletion affects the formation of tight junctions in these cells. Furthermore, we show that reduced expression of PARD3 is associated with the aggressiveness of primary ESCC tumors.
Results

Identification of homozygous deletion of PARD3
To identify genes potentially involved in ESCC, we screened for DNA copy number aberrations in 20 ESCC cell lines by Affymetrix GeneChip Mapping 250K array analysis. Of the 20 cell lines screened, KYSE30 and KYSE270 cells exhibited homozygous deletions at the chromosomal region 10p11 (Figure 1a ). The estimated extent of the common region of deletion was B280 kb between the markers SNP_A-2051960 and SNP_A-1867256, which includes a single gene PARD3 (Supplementary Figure S1 ). The extent of the shortest region of overlap of homozygous deletions was narrowed down to exons 3-22 of PARD3 by genomic PCR analyses (Figures 1b and c) .
Copy number and expression of PARD3 in ESCC cell lines We analysed the DNA copy number and expression level of PARD3 in 20 ESCC cell lines and normal lymphocytes and in esophageal epithelial cells as a control (Figure 2 ). Comparison with normal esophageal epithelial cells showed lower expression of PARD3 in 18 of the 20 ESCC cell lines (Figure 2b ). The absence of the PARD3 gene in the KYSE30 and KYSE270 cell lines was confirmed by real-time quantitative reverse transcription (RT)-PCR and immunoblot analyses. These assays did not detect the expression of PARD3 mRNA and the PAR-3 protein, respectively (Figures 2b and c) . Analyses of the cell lines by real-time quantitative RT-PCR and immunoblot indicated varying expression levels of PARD3 mRNA, and three forms of the PAR-3 protein with molecular weights of 180, 150 and 100 kDa, respectively (Figures 2b and c) .
PAR-3-dependent recruitment of ZO-1 to sites of cell-cell contact in ESCC cells To determine whether the deletion of PARD3 leads to defective tight junction formation in ESCC cells, we determined the effect of PARD3 deletion on the subcellular localization of zonula occludens 1 (ZO-1), a marker of cellular tight junctions (Stevenson et al., 1986) . For this purpose, we compared the colocalization (Figure 3a) . In contrast, ZO-1 was only weakly observed at sites of cellcell contact in KYSE30 cells and was barely detected in KYSE270 cells (Figure 3a) , despite the fact that the ZO-1 protein could be detected by immunoblotting in all cell lines ( Figure 3b ). As expected, the expression of PAR-3 was not detected in KYSE30 or KYSE270 cells (Figure 3a) . To further confirm that the absence of PAR-3 was the cause of the aberrant localization of ZO-1 in the KYSE30 and KYSE270 cells, we determined whether transfection of PARD3 into these cells could restore ZO-1 localization to tight junctions. After transfection, the expression of PAR-3 (molecular weight, 180 kDa) in the PARD3-transfected KYSE30 and KYSE270 cells was detected by immunoblotting analysis (Figure 4a ). ECGI-10  KYSE30  KYSE70  KYSE110  KYSE140  KYSE150  KYSE220  KYSE270   TE1  TE4  TE5  TE6  TE8  TE9  TE10  TE11  TE14  TE15   T.T  T.Tn  ECGI-10  KYSE30  KYSE70  KYSE110  KYSE140  KYSE150  KYSE220  KYSE270   TE1  TE4  TE5  TE6  TE8  TE9  TE10  TE11  TE14  TE15  normal TE1  TE4  TE5  TE6  TE8  TE9  TE10  TE11  TE14  TE15 normal esophagus β-actin 
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Immunocytochemistry showed that, in addition to a diffuse staining, PAR-3 could now be detected in a linear manner at cell-cell borders in the PARD3-transfected KYSE30 and KYSE270 cells, in which it colocalized with ZO-1 (Figure 4b ). Transfection of PARD3 led to a stronger staining of ZO-1 at sites of cell-cell contact compared with control-transfected cells ( Figure 4b ). This was despite the fact that the total level of ZO-1 was the same in PARD3 and control transfectants ( Figure 4c ). Knockdown of the PARD3 expression in T.T cells was carried out using RNA interference (RNAi). After treatment of T.T cells with small interfering RNA (siRNA) targeting PARD3, we observed a decrease in the PAR-3 protein level relative to that observed for cells receiving negative control siRNA, transfection agent alone or left untreated ( Figure 4a) . Suppression of the PAR-3 expression by siRNA caused a disruption of localization of ZO-1 at cell-cell borders (Figure 4b) , although the total level of ZO-1 was unchanged (Figure 4c ). Taken together, these findings suggest that PAR-3 promotes the recruitment of ZO-1 to sites of cell-cell contact.
PAR-3 and cell migration
To investigate the role of PAR-3 in cell motility, we performed a monolayer wound-healing assay in knockdown T.T cells. Knockdown of the PARD3 expression was conducted as described above. Wound closure was shown to be unchanged among PARD3 siRNA-treated cells, negative control siRNA-treated cells and untreated cells (Supplementary Figure S2) . 
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This suggests that the suppression of PAR-3 may not affect cell migration.
Analysis of PARD3 defects in primary tumors
To determine whether the loss of PARD3 observed in KYSE30 and KYSE270 carcinoma cell lines was relevant to primary carcinomas in humans, we first determined the DNA copy number of PARD3 in 40 primary ESCC tumors (Figure 5a ). For this analysis, the values were normalized such that the copy number in genomic DNA derived from normal lymphocytes was given a value of 1. Copy number changes were counted as losses if the results of the analysis for a given ESCC tumor were o0.7 (Berggren et al., 2003) . Using these parameters, a copy number loss of PARD3 was observed in 6 (15%) of the 40 tumors. We then further quantified the mRNA levels of PARD3 in the available paired tumor and nontumor tissues from 33 ESCC patients (Figure 5b ). Patient and tumor characteristics are summarized in Supplementary   Table S2 . The expression of PARD3 mRNA was significantly reduced in 23 (70%) of the 33 tumors when compared with their nontumorous tissue counterparts (Wilcoxon signed-rank test, P ¼ 0.017). To clarify the relationship between the expression level of PARD3 and various clinicopathological parameters, we correlated the PARD3 expression level with clinical data that was available for 28 of the patients. For this purpose, tumors were divided into one of two groups based on reduction in PARD3 levels: tumor tissue (T) onontumor tissue (NT), or not reduced (TXNT). Reduced expression of PARD3 was significantly associated with a younger age (p65 years), positive lymph node metastasis and poor differentiation (Table 1 ). These findings suggest that reduced expression of PARD3 is important not only for cancer cell lines but also for the tumorigenic properties of primary tumors. and nontumor tissues (NT) from 33 patients with primary ESCCs was determined as described in Figure 2b . P-values of o0.05 were considered significant. (Friend et al., 1986; Kamb et al., 1994; Hahn et al., 1996; Li et al., 1997) . A putative tumor suppressor is believed to lie on the chromosomal region 10p in ESCC (Aoki et al., 1994) . In this study, using highdensity SNP arrays, we identified a novel homozygous deletion at the chromosomal region 10p11 in 2 out of 20 ESCC cell lines. Subsequent detailed analyses narrowed down the extent of the shortest region of overlap of the homozygous deletions to exons 3-22 of the gene PARD3.
Recently, homozygous deletion of PARD3 has been reported in two lung cancer cell lines (Nagayama et al., 2007) . A few studies have suggested an association of PARD3 with tumors (Fang and Xu, 2001; Zitzelsberger et al., 2004) , and PARD3 was reported to be amplified in radiation-transformed neoplastic retinal pigment epithelial cell lines (Zitzelsberger et al., 2004) . Also, various splicing transcripts of PARD3 are expressed in primary hepatocellular carcinomas, and the expression of exon 17b deleted PARD3 variants is downregulated in these carcinomas compared with the surrounding nontumorous liver tissues (Fang and Xu, 2001 ). However, the biological function of PARD3 and its clinical significance for cancer are poorly understood. In this study, a gain of PARD3 copy number (defined as twice the level of normal DNA) was observed in only 1 of the 20 ESCC cell lines tested (TE4 cells) and in none of the 40 primary ESCC tumors analysed. Conversely, a loss of PARD3 was detected in 15% of the primary ESCC tumors examined, and a reduced expression of PARD3 mRNA was found in primary ESCC tumors compared with their nontumorous counterparts. The reduced expression of PARD3 was associated with aggressive ESCC phenotypes, such as positive lymph node metastasis and poor differentiation. To validate these results at the protein level, we unsuccessfully tried to carry out the immunohistochemical analysis of PAR-3 on formalinfixed and paraffin-embedded sections of primary ESCC specimens. We assume that the anti-PAR-3 antibody is not suitable for formalin-fixed and paraffin-embedded sections. Further studies in more numerous primary samples and studies using immunohistochemistry are needed to determine the clinical importance of PAR-3 in ESCC.
PAR-3 has been implicated in the formation of normal tight junctions at epithelial cell-cell contacts (Joberty et al., 2000; Macara, 2004; Chen and Macara, 2005; Suzuki and Ohno, 2006) . PAR-3 plays the role of a scaffold in the recruitment of proteins, such as PAR-6 or aPKC, that are involved in the formation of these junctions (Asse´mat et al, 2008) . In agreement with these data, our immunocytochemical analyses showed that PAR-3 colocalized with the tight junction component, ZO-1, at sites of cell-cell contact in T.T and TE-4 cells that express PARD3. Unexpectedly, ZO-1 was weakly detected at sites of cell-cell contact in KYSE30 cells that lack PARD3. On the other hand, ZO-1 was barely detected in KYSE270 cells, which also lack PARD3. Exogenous expression of PARD3 resulted in the recruitment of ZO-1 to sites of cell-cell contact in KYSE30 and KYSE270 cells without affecting the expression level of ZO-1. Conversely, knockdown of PARD3 in T.T cells that express this gene caused a disruption of localization of ZO-1 at cell-cell borders. Taken together, these findings suggest that PAR-3 promotes the recruitment of ZO-1 to sites of cell-cell contact, although it may not always be essential for this localization of ZO-1. The finding that PARD3 affects the formation of tight junction in ESCC cells might partially explain the observed association between the reduced expression of PARD3 and positive lymph node metastasis, and between poor differentiation of primary ESCCs. However, our wound-healing assay did not show any effect of PAR-3 on cell migration. Further functional studies are needed to determine the implication of PAR-3 in ESCC invasion and metastasis.
Our finding that PAR-3 is important, but not essential, for tight junction formation and ZO-1 recruitment are in partial agreement with previous observations. The targeted disruption of the mouse PAR-3 gene (Pard3) results in embryonic lethality with defective epicardial development (Hirose et al., 2006) . Pard3-deficient epicardial progenitor cells do not form epicardial cysts from which the epicardium is derived. These cells show defects in the localization of PAR-6 and aPKC to the apical domain, but a normal localization of ZO-1 to cell-cell junctions. Interestingly, not all epithelial cells are affected in the Pard3-deficient embryo, which may be due to the proposed functional redundancy of PAR-3 and the PAR-3-related protein PAR-3L/PAR-3b (Gao et al., 2002; Kohjima et al., 2002) . The function of PAR-3 has also been examined in MDCK II canine epithelial cells (Chen and Macara, 2005) . In that study, withdrawal of calcium from the medium caused rapid loss of cell-cell junctions, which could be reversed by the re-addition of calcium (a calcium switch experiment). The normal relocalization of tight junction components at cell-cell contacts within 30 min after re-addition of calcium was profoundly delayed in cells lacking PAR-3, although tight junctions could eventually form even without re-expression of PAR-3.
The exact mechanism by which PAR-3 modulates tight junctions and contributes to tumorigenicity remains to be elucidated. Besides PAR-6 and aPKC, PAR-3 also interacts with other proteins such as 14-3-3, LIMK2 and the Rac-specific guanine nucleotide exchange factor STEF/Tiam1 (Humbert et al., 2006; Asse´mat et al., 2008) . Moreover, recent studies have shown that the PAR-3-PAR-6-aPKC complex associates with the tumor suppressor VHL (von Hippel-Lindau protein) or with PTEN (phosphatase and tensin homologue deleted on chromosome ten) (Wodarz and Na¨thke, 2007) , suggesting potential mechanisms by which PAR-3 might modulate tumorigenicity. Although the mechanism of PAR-3 function in tumors remains to be elucidated and the findings must be verified in a larger sample number, the data presented in this work clearly suggest a role for PAR-3 deletion in the tumorigenesis of ESCC.
Materials and methods
Cell lines and primary tumors
The ESCC cell lines TE-1, TE-5, TE-9, TE-15 and EC-GI-10 were obtained from RIKEN Bioresource Center (Tsukuba, Japan); T.T, T.Tn, KYSE30, KYSE70, KYSE110, KYSE140, KYSE150, KYSE220 and KYSE270 were from Japan Health Sciences Foundation (Osaka, Japan); and TE-4, TE-6, TE-8, TE-10, TE-11 and TE-14 were from Cell Resource Center for Biomedical Research, Tohoku University (Sendai, Japan). All cell lines were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Genomic DNA was isolated from the cell lines with the DNeasy Mini Kit (Qiagen, Tokyo, Japan).
Paired tumor and nontumor tissues were obtained during upper gastrointestinal endoscopic inspection from 40 ESCC patients who underwent biopsy for diagnostic purposes at the Hospital of Kyoto Prefectural University of Medicine (Kyoto, Japan). All biopsy specimens were immediately frozen in liquid nitrogen and stored at À80 1C until required. Genomic DNA and total RNA were isolated from primary samples with the AllPrep DNA/RNA Mini Kit (Qiagen). All tumor samples were available for DNA analyses, and 33 paired tumor and nontumor samples were available for mRNA analyses. Before the study, informed consent was obtained and the study was approved by ethics committees.
Array analysis
Array analyses were carried out with the GeneChip Mapping 250K Sty array (Affymetrix, Santa Clara, CA, USA) according to the manufacturer's instructions. In brief, 250 ng of genomic DNA was digested with a restriction enzyme (StyI), ligated to an adaptor and amplified by PCR. Amplified products were fragmented, labeled by biotinylation and hybridized to the microarrays. Hybridization was detected by incubation with streptavidin-phycoerythrin conjugates, followed by scanning of the array, and analysis was carried out as described earlier (Kennedy et al., 2003) . Copy number changes were calculated using the Copy Number Analyzer for Affymetrix GeneChip Mapping Arrays (CNAG; http://www.genome.umin.jp; Nannya et al., 2005) .
PCR analysis
Conventional PCR was performed using Ex Taq DNA Polymerase (Takara, Otsu, Japan) as described by the manufacturer. Genomic DNA and mRNA were quantified with a real-time fluorescence detection method as described earlier (Inagaki et al., 2008) . Total RNA derived from normal human esophageal epithelial cells was purchased from Ambion (Austin, TX, USA). Single-stranded cDNAs were generated from total RNAs using QuantiTect Reverse Transcription Kit (Qiagen). Primers used for genomic PCR and RT-PCR are listed in Supplementary Table S1 . Endogenous controls for mRNA and genomic DNA levels were ACTB and the long interspersed nuclear element 1 (LINE-1) (Zhao et al., 2004) , respectively.
Immunoblotting
Immunoblots were prepared according to the previously reported methods (Yasui et al., 2001) . Cell lysates (20 mg protein per sample) were separated by SDS-polyacrylamide gel electrophoresis using 10% acrylamide gels. The anti-PAR-3 polyclonal antibody was obtained from Upstate Biotechnology (Lake Placid, NY, USA), the anti-b-actin monoclonal antibody from Sigma-Aldrich (Tokyo, Japan) and the anti-ZO-1 monoclonal antibody from Zymed (South San Francisco, CA, USA). The anti-PAR-3, anti-ZO-1 and anti-b-actin antibodies were used for immunoblotting at dilutions of 1:500, 1:250 and 1:5000, respectively. For secondary immunodetection, anti-rabbit or anti-mouse immunoglobulin (Ig) (Amersham, Tokyo, Japan) was diluted 1:5000. Protein binding was detected using the ECL system (Amersham).
Transient expression of PARD3
The full-length human PARD3 cDNA (clone ID: IOH62499) was obtained from Invitrogen (Carlsbad, CA, USA) and was subcloned into pcDNA3.2/V5-DEST vector (Invitrogen) to generate a mammalian expression vector. The PARD3 expression vector, or an empty vector, was transfected into KYSE30 and KYSE270 cells using the Effectene Transfection Reagent Kit (Qiagen) according to the manufacturer's instructions. After 48 h incubation, the cell lysates were analysed by immunoblotting for detection of the expression of PAR-3 protein.
RNAi
Small interfering RNA duplex oligoribonucleotides targeting PARD3 (5 0 -AAUGAUGGGUGUACGCAUGGCUUGG-3 0 ) and control (non-silencing) siRNA duplexes were synthesized by Invitrogen in order to investigate the role of PAR-3 in ZO-1 localization and cell motility. The siRNAs were delivered into T.T cells using Lipofectamine RNAiMAX (Invitrogen), according to the manufacturer's protocol.
Immunofluorescence microscopy KYSE30 and KYSE270 cells were transfected with the PARD3 expression vector or the empty vector. T.T cells were transfected with either siRNA targeting PARD3 or negative control siRNA. After 24 h incubation, the cells were collected, reseeded on glass slides and incubated overnight. The cells were fixed with 3.7% formaldehyde, permeabilized with 0.2% Triton X-100 and incubated with phosphate-buffered saline containing 1% bovine serum albumin. The cells were then treated with a mixture of anti-PAR-3 and anti-ZO-1 antibodies at a dilution of 1:500 and 1:100, respectively, for 1 h at 37 1C. The second antibodies used were a mixture of fluorescein isothiocyanate-conjugated anti-rabbit Ig (Cappel, Aurora, OH, USA) and rhodamine-conjugated anti-mouse Ig (Cappel) for the detection of PAR-3 and ZO-1, respectively. Samples were examined using a confocal laser scanning microscope (SV1000; Olympus, Tokyo, Japan).
Monolayer wound healing assay T.T cells were transfected with either siRNA targeting PARD3 or negative control siRNA, or left untreated. After 24 h, cells in Dulbecco's modified Eagle's medium with 1% fetal bovine serum were seeded on glass slides and allowed to adhere overnight. Wounds were scratched into the cell monolayer using a sterile 200-ml pipette tip, rinsed the cells with phosphate-buffered saline and added Dulbecco's modified Eagle's medium containing 10% fetal bovine serum with mitomycin C (0.5 mg/ml, Nacalai Tesque, Kyoto, Japan). Mitomycin C blocks mitosis and thus allows analysis of cell migration in the absence of cell proliferation. Cells were allowed to migrate into the wound over a period of 24 h before fixation. Wound widths were measured in three randomly selected regions at 0, 12 and 24 h after wounding. Cells were stained with Giemsa stain (Nacalai Tesque, Kyoto, Japan). Experiments were repeated at least three times.
